Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.66
+0.42 (5.10%)
At close: Apr 14, 2026, 4:00 PM EDT
8.66
0.00 (0.00%)
After-hours: Apr 14, 2026, 7:00 PM EDT
Emergent BioSolutions Revenue
In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%. Emergent BioSolutions had revenue of $148.70M in the quarter ending December 31, 2025, a decrease of -23.63%.
Revenue (ttm)
$742.90M
Revenue Growth
-28.81%
P/S Ratio
0.60
Revenue / Employee
$825,444
Employees
900
Market Cap
447.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
| SIGA Technologies | 94.57M |
EBS News
- 5 days ago - Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program - GlobeNewsWire
- 7 days ago - Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness - GlobeNewsWire
- 12 days ago - Emergent BioSolutions Participates in Upcoming International Preparedness Conferences - GlobeNewsWire
- 20 days ago - Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures - GlobeNewsWire
- 4 weeks ago - Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look. - Barrons
- 6 weeks ago - Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness - GlobeNewsWire